Novartis– tag –
-
Where Will Nuclear Medicine Be in the Next Decade? Ac-225, Pb-212, and the Next-Generation RI Pipeline Map | Vol.3 (Final)
Nuclear medicine next decade: shift from β (177Lu) to α (225Ac, 212Pb). α has 100× cytotoxicity, short range protects normal tissue. Pipelines: 225Ac-PSMA, 225Ac-FAP, 225Ac-DOTATATE (RYZ101), 212Pb-DOTAMTATE. New targets (FAP, GD2, HER2, αvβ6). Manufacturing wall (Oak Ridge, Karlsruhe, PSI, JAEA). Final volume. -
Mapping Nuclear Medicine Competitors: Lantheus, Bayer, Telix and the 3 Turning Points Ahead | Vol.2
Comparison of nuclear medicine competitors (Lantheus, Bayer, Telix, Lilly × Mariana, BMS × RayzeBio, AZ × Fusion) across 5 axes: diagnostic vs treatment, target molecules, isotopes, manufacturing infrastructure, partnerships. Emerging specialists (Aktis, Convergent, Perspective, Curasight, Clarity) and industry reshuffling scenarios. Vol. 2. -
Where Is Nuclear Medicine Heading? Pluvicto’s Success and the Vertical Integration Imperative | Nuclear Medicine Vol.1
Novartis Pluvicto (mCRPC, $1B+ annual revenue) and Lutathera (NET) clinical and commercial success moved nuclear medicine from niche to mainstream. Short isotope half-life and specialized facility requirements make Vertical Integration (production-synthesis-distribution-delivery chain) decisive competitive advantage. Endocyte acquisition $2.1B, Point Biopharma $1.4B, 14-site global manufacturing network. Vol. 1. -
Biotech Investment News: Novartis’s Key Deals from 2015 to 2025
Strategic Review: From Blockbusters to Nuclear Medicine, Gene and Cell Therapy Over the past decade, Novartis has strategically shifted its focus toward high-value therapies, including nuclear medicine (Pluvicto), gene therapy (Z Over th...
1